KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Equity Ratio: 2020-2025

Historic Equity Ratio for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to 0.71.

  • AbCellera Biologics' Equity Ratio fell 8.15% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year decrease of 8.15%. This contributed to the annual value of 0.78 for FY2024, which is 0.24% up from last year.
  • AbCellera Biologics' Equity Ratio amounted to 0.71 in Q3 2025, which was down 1.02% from 0.72 recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Equity Ratio registered a high of 0.85 during Q1 2021, and its lowest value of 0.71 during Q3 2025.
  • In the last 3 years, AbCellera Biologics' Equity Ratio had a median value of 0.77 in 2023 and averaged 0.77.
  • As far as peak fluctuations go, AbCellera Biologics' Equity Ratio fell by 10.59% in 2022, and later grew by 6.39% in 2023.
  • AbCellera Biologics' Equity Ratio (Quarterly) stood at 0.78 in 2021, then grew by 2.89% to 0.80 in 2022, then declined by 3.25% to 0.77 in 2023, then increased by 0.24% to 0.78 in 2024, then decreased by 8.15% to 0.71 in 2025.
  • Its last three reported values are 0.71 in Q3 2025, 0.72 for Q2 2025, and 0.76 during Q1 2025.